Clinical Trial Update: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial is evaluating the lowest effective dose of post-transplant cyclophosphamide in combination with sirolimus and mycophenolate mofetil to prev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Sirolimus (Sirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Status: RECRUITING